Endothelial progenitor cell migration and differentiation (EPC migration/differentiation (no widely used abbreviation for the combined process))

Endothelial progenitor cells (EPCs) are pluripotent stem/progenitor cells primarily derived from bone marrow that have the capacity to migrate ("homing") to sites requiring vascular repair or new blood vessel formation. Upon recruitment through multistep adhesive interactions involving integrins and chemokine receptors like CXCR4 responding to SDF1/CXCL12 gradients, they transmigrate through existing endothelium into ischemic or injured tissue. Thereafter they differentiate into mature endothelial cells contributing directly to reendothelialization and neovascularization. This complex biological process involves secretion of various paracrine factors including VEGF isoforms which promote maturation; macrophage migration inhibitory factor which influences smooth muscle cell lineage commitment; fibroblast growth factors; among others. The balance between signals determines whether these progenitors maintain an undifferentiated state or progress toward functional endothelium. The molecular regulation includes key pathways such as Akt for survival/differentiation promotion while other molecules like VEGI can inhibit early-stage differentiation by downregulating integrins critical for adhesion/migration. The exact genetic cascades remain incompletely understood but involve homeobox genes like ETV2 during embryonic development analogously influencing adult stem cell fate. Clinically, enhancing endogenous or ex vivo expanded EPC function holds promise for treating cardiovascular diseases characterized by ischemia through improved vascular regeneration. However therapeutic application requires careful modulation due to potential risks related to aberrant angiogenesis in tumors or other pathologies. In summary, "Endothelial progenitor cell migration/differentiation" describes essential physiological processes whereby circulating bone marrow-derived precursor cells home towards damaged vasculature sites then differentiate into mature endothelium facilitating tissue repair via new vessel formation[1][3][4][6].

Other names

Endothelial progenitor cells (EPCs)endothelial progenitor cell homingEPC-mediated neovascularizationendothelial lineage differentiation of EPCs

Drugs modulate this process mainly by: - Stimulating or inhibiting signaling pathways involved in adhesion, chemoattraction, survival, proliferation, and maturation of EPCs. - VEGF promotes differentiation via VEGF receptors activating Akt pathway. - VEGI inhibits Akt activation leading to reduced integrin expression and impaired adhesion/migration[5]. - Statins enhance mobilization from bone marrow niche[6].